Try
MeiraGTx Holdings plc
MGTXUnited States
33 filed reports · 505 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
33 reports · Jun 2018 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 25 | 3,959 | Jun 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 3,112 | Dec 2018 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 13, 2026 | 400 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 14, 2026 | 271 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 30, 2026 | 634 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 13, 2025 | 245 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 14, 2025 | 156 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 13, 2025 | 131 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 13, 2025 | 345 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 146 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 12, 2024 | 122 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 127 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 15, 2024 | 346 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 14, 2023 | 145 | Open |
Financial data
505 concepts · 7,071 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial483 concepts · 6,981 facts · Jun 2017 to Jun 2026
- Clinical trial costs61 · Dec 2017 to Jun 2026
- Research and development52 · Dec 2017 to Jun 2026
- Manufacturing costs49 · Sep 2019 to Jun 2026
- Allocated share based compensation expense46 · Jun 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents46 · Jun 2017 to Jun 2026
- Comprehensive income net of tax46 · Jun 2017 to Jun 2026
- Foreign currency transaction gain loss before tax46 · Jun 2017 to Jun 2026
- General and administrative expense (US GAAP)46 · Jun 2017 to Jun 2026
- Interest expense (US GAAP)46 · Jun 2017 to Jun 2026
- Net income loss46 · Jun 2017 to Jun 2026
- Net income loss available to common stockholders basic46 · Jun 2017 to Jun 2026
- Operating expenses (US GAAP)46 · Jun 2017 to Jun 2026
- Operating income loss46 · Jun 2017 to Jun 2026
- Research and development expense46 · Jun 2017 to Jun 2026
- Amortization of interest on asset retirement obligations45 · Sep 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect45 · Sep 2017 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents45 · Sep 2017 to Jun 2026
- Increase decrease in accounts payable45 · Sep 2017 to Jun 2026
- Increase decrease in accrued liabilities45 · Sep 2017 to Jun 2026
- Increase decrease in other current assets45 · Sep 2017 to Jun 2026
- Interest paid net45 · Sep 2017 to Jun 2026
- Investment income interest45 · Jun 2017 to Jun 2026
- Net cash provided by used in financing activities45 · Sep 2017 to Jun 2026
- Net cash provided by used in investing activities45 · Sep 2017 to Jun 2026
Geography4 concepts · 42 facts · Dec 2018 to Dec 2025
- Deferred foreign income tax expense benefit16 · Dec 2018 to Dec 2023
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest12 · Dec 2022 to Dec 2024
- Ireland8 · Dec 2022 to Dec 2025
- Deferred federal income tax expense benefit6 · Dec 2018 to Dec 2023
Segment17 concepts · 34 facts · Jun 2025 to Jun 2026
- Revenue4 · Jun 2025 to Jun 2026
- AAV-GAD2 · Jun 2025 to Jun 2026
- AAV-hAQP12 · Jun 2025 to Jun 2026
- Depreciation depletion and amortization2 · Jun 2025 to Jun 2026
- General and administrative2 · Jun 2025 to Jun 2026
- Gene Regulation2 · Jun 2025 to Jun 2026
- Manufacturing2 · Jun 2025 to Jun 2026
- Net income loss2 · Jun 2025 to Jun 2026
- Neurodegenerative diseases2 · Jun 2025 to Jun 2026
- Operating expenses (US GAAP)2 · Jun 2025 to Jun 2026
- Other research and development (1)2 · Jun 2025 to Jun 2026
- Other segment items (2)2 · Jun 2025 to Jun 2026
- Preclinical ocular diseases2 · Jun 2025 to Jun 2026
- Segment net loss2 · Jun 2025 to Jun 2026
- Share based compensation2 · Jun 2025 to Jun 2026
- Botaretigene Sparoparvovec1 · Jun 2026
- Other ocular diseases1 · Jun 2025
Product1 concepts · 14 facts · Jun 2024 to Jun 2026
- Revenue14 · Jun 2024 to Jun 2026
Segments
90 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographical7 members · 42 facts
- IE10 · Dec 2020 to Dec 2025
- GB9 · Dec 2018 to Dec 2024
- US9 · Dec 2018 to Dec 2024
- BE4 · Dec 2022 to Dec 2025
- NL4 · Dec 2019 to Dec 2023
- Non Us3 · Dec 2022 to Dec 2024
- Other Countries3 · Dec 2020 to Dec 2022
Statement business segments1 member · 34 facts
- Single Reportable34 · Jun 2025 to Jun 2026
Product or service4 members · 14 facts
- Related Party Service Revenue11 · Jun 2024 to Jun 2026
- License1 · Dec 2025
- Related Party License Revenue1 · Jun 2026
- Service1 · Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.